Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 12/20 | 0.61 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365993 | 0.90 | HPGDS (0.66) | HPGDSKDM1AROCK2ROCK1WNT1 | |
| SCHEMBL1365099 | 0.87 | HPGDS (0.59) | HPGDSKDM1APRKAA2ROCK2ROCK1 | |
| SCHEMBL347916 | 0.85 | HPGDS (0.80) | HPGDSKDM1AROCK2ROCK1WNT1 | |
| SCHEMBL1366617 | 0.85 | HPGDS (0.66) | HPGDSKDM1APRKAA2ROCK2ROCK1 | |
| SCHEMBL1367370 | 0.85 | HPGDS (0.65) | HPGDSKDM1APRKAA2ROCK2ROCK1 | |
| SCHEMBL1366918 | 0.85 | HPGDS (0.65) | HPGDSKDM1AROCK2ROCK1WNT1 | |
| SCHEMBL1365097 | 0.84 | HPGDS (0.68) | HPGDSKDM1AROCK2ROCK1WNT1 | |
| SCHEMBL1364494 | 0.84 | HPGDS (0.61) | HPGDSKDM1APRKAA2ROCK2ROCK1 | |
| SCHEMBL1367082 | 0.84 | HPGDS (0.78) | HPGDSKDM1APRKAA2ROCK2ROCK1 | |
| SCHEMBL1365857 | 0.84 | HPGDS (0.64) | HPGDSKDM1APRKAA2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885KDM1A 2416/4885PRKAA2 3883/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885KDM1A 2416/4885PRKAA2 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.